Search results for "RSE"

showing 10 items of 11150 documents

Methods for RNA Modification Mapping Using Deep Sequencing: Established and New Emerging Technologies

2019

New analytics of post-transcriptional RNA modifications have paved the way for a tremendous upswing of the biological and biomedical research in this field. This especially applies to methods that included RNA-Seq techniques, and which typically result in what is termed global scale modification mapping. In this process, positions inside a cell`s transcriptome are receiving a status of potential modification sites (so called modification calling), typically based on a score of some kind that issues from the particular method applied. The resulting data are thought to represent information that goes beyond what is contained in typical transcriptome data, and hence the field has taken to use …

0301 basic medicinelcsh:QH426-470Computer scienceProcess (engineering)Emerging technologieschemical treatmentNext Generation Sequencingengineered Reverse Transcriptase enzymesRNA-SeqReviewcomputer.software_genreDeep sequencingField (computer science)deep sequencing03 medical and health sciences0302 clinical medicineepitranscriptome[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]GeneticsAnimalsHumansRNA-SeqRNA Processing Post-TranscriptionalComputingMilieux_MISCELLANEOUSGenetics (clinical)Sequence Analysis RNAbusiness.industryScale (chemistry)High-Throughput Nucleotide Sequencing[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyRNA modificationTerm (time)lcsh:Genetics030104 developmental biologyAnalyticsRNAData miningbusinesscomputer030217 neurology & neurosurgeryGenes
researchProduct

Manganese Ions Individually Alter the Reverse Transcription Signature of Modified Ribonucleosides

2020

Reverse transcription of RNA templates containing modified ribonucleosides transfers modification-related information as misincorporations, arrest or nucleotide skipping events to the newly synthesized cDNA strand. The frequency and proportion of these events, merged from all sequenced cDNAs, yield a so-called RT signature, characteristic for the respective RNA modification and reverse transcriptase (RT). While known for DNA polymerases in so-called error-prone PCR, testing of four different RTs by replacing Mg2+ with Mn2+ in reaction buffer revealed the immense influence of manganese chloride on derived RT signatures, with arrest rates on m1A positions dropping from 82% down to 24%. Additi…

0301 basic medicinelcsh:QH426-470DNA polymerasechemistry.chemical_elementManganeseSaccharomyces cerevisiaeRT signature[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biology01 natural sciencesArticle03 medical and health sciencesm1ARNA modificationsComplementary DNA[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]GeneticsNucleotidem<sup>1</sup>ABase PairingGenetics (clinical)PolymeraseComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationIonsManganesebiology010405 organic chemistryRNARNA-Directed DNA Polymerase[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyreverse transcriptionMolecular biologyReverse transcriptase0104 chemical scienceslcsh:Genetics030104 developmental biologyTemplatechemistrybiology.proteinRNA[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Ribonucleosidesmanganese chloride
researchProduct

Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial.

2015

Antibiotic-associated diarrhea is an important clinical problem, associated with morbidity, mortality and healthcare costs. Our randomized, placebo controlled multicenter trial do not support the efficacy of Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea.

0301 basic medicinemedicine.medical_specialty030106 microbiologyPopulationPlacebo-controlled studyPlacebolaw.inventionMajor Articles03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdverse effecteducationeducation.field_of_studybiologybusiness.industrybiology.organism_classificationClostridium difficile-associated diarrheaDiscontinuationSurgerySaccharomyces boulardiiInfectious DiseasesOncologyantibiotic-associated diarrhearandomized controlled trial030211 gastroenterology & hepatologyAntibiotic-associated diarrheabusinessprobioticSaccharomyces boulardiiOpen forum infectious diseases
researchProduct

Is it time to combine untargeted antifungal strategies to reach the goal of 'early' effective treatment?

2016

A recently published retrospective study by Posteraro et al. [1] investigated the use of (1–3)-β-D-glucan (BDG) as a strategy for antifungal drug administration in patients at high risk of candidemia. The strategy consisted of the administration of antifungals (anidulafungin in most cases) to septic patients with a Candida score ≥ 3a nd a positive BDG result (≥80 pg/ml). This untargeted strategy led to better selection of patients, avoiding exposure to antifungals in approximately 73 % of patients with negative BDG results and leading to shortened treatment duration in another 20 % of patients. Untargeted antifungal treatments (including prophylaxis, pre-emptive and empiric approaches) are …

0301 basic medicinemedicine.medical_specialtyAntifungal Agents030106 microbiologyAntifungal drugCritical Care and Intensive Care Medicinelaw.inventionGoal03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumans; Treatment Outcome; Antifungal Agents; Goals; Critical Care and Intensive Care MedicineAntifungal AgentHumansStage (cooking)MED/41 - ANESTESIOLOGIAAdverse effectIntensive care medicineSurrogate endpointbusiness.industryIncidence (epidemiology)030208 emergency & critical care medicineRetrospective cohort studyTreatment OutcomeAnidulafunginbusinessGoalsmedicine.drugHumanCritical care (London, England)
researchProduct

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO…

2017

The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account t…

0301 basic medicinemedicine.medical_specialtyChinaColorectal cancerDrug availabilityEthnic groupTaiwanConsensuSystemic therapyScientific evidence03 medical and health sciences0302 clinical medicineAsian PeopleRepublic of KoreaAsian countrymedicineHumansNeoplasm MetastasisReimbursementClinical OncologyClinical practice guidelinePan-Asianbusiness.industryMalaysiaHematologymedicine.diseaseColorectal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicinebusinessColorectal NeoplasmsAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region

2019

Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low …

0301 basic medicinemedicine.medical_specialtyConsensusEndocrinology Diabetes and MetabolismOsteoporosis030209 endocrinology & metabolismBone resorption makerAsia pacific regionCollagen Type IBone remodeling03 medical and health sciences0302 clinical medicineN-terminal telopeptideBone DensityOsteoporosis treatmentHealth caremedicineHumansRadiology Nuclear Medicine and imagingOrthopedics and Sports MedicineIntensive care medicineReimbursementAnabolicsBone mineralddc:616Hip Fracturesbusiness.industryAnti-resorptivesmedicine.diseasePeptide FragmentsBone formation makerOsteoporosisBone Remodeling030101 anatomy & morphologybusinessBiomarkersProcollagen
researchProduct

Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP)

2020

Abstract Acute and chronic physical exercises may enhance the development of statin-related myopathy. In this context, the recent (2019) guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) for the management of dyslipidemias recommend that, although individuals with dyslipidemia should be advised to engage in regular moderate physical exercise (for at least 30 min daily), physicians should be alerted with regard to myopathy and creatine kinase (CK) elevation in statin-treated sport athletes. However it is worth emphasizing that abovementioned guidelines, previous and recent ESC/EAS consensus papers on adverse effects of statin therapy as wel…

0301 basic medicinemedicine.medical_specialtyConsensusSports medicineContext (language use)Physical exercise03 medical and health sciences0302 clinical medicineAthlethsMuscular DiseasesStatin intoleranceMedicineHumansAdverse effectAthlethExerciseMylagiaDyslipidemiasPharmacologybiologybusiness.industryAthletesExercisesAthleths Exercises Management Mylagia Statin intolerance.Athleths; Exercises; Management; Mylagia; Statin intolerancemedicine.diseasebiology.organism_classificationManagement030104 developmental biologyAthletes030220 oncology & carcinogenesisPhysical therapyPosition paperStatin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

P164 Cyclophosphamide for the treatment of refractory chronic hypersensitivity pneumonitis

2018

Introduction Intravenous cyclophosphamide at a dose of 600 mg/m2 monthly for 6 months is an established treatment for various immune modulated interstitial lung diseases (ILDs). This practice has been extended to rapidly progressive chronic hypersensitivity pneumonitis (CHP), however, little is known about the therapeutic efficacy in this disease. Methods All patients receiving intravenous cyclophosphamide between 2007 and 2017 at the Royal Brompton Hospital were identified using pharmacy records. Those with a clinical diagnosis of CHP underwent MDT review to confirm the diagnosis. Clinical data, demographics and lung function at time of first treatment and 12 months pre- and post was captu…

0301 basic medicinemedicine.medical_specialtyCyclophosphamideNauseabusiness.industrymedicine.diseaseDiscontinuation03 medical and health sciencesFEV1/FVC ratio030104 developmental biology0302 clinical medicineDLCO030220 oncology & carcinogenesisInternal medicineCohortmedicineVomitingmedicine.symptombusinessHypersensitivity pneumonitismedicine.drugUpdates on treatment, prognosis and outcomes in ILD
researchProduct

What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects

2020

Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short…

0301 basic medicinemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsCoronavirus disease 2019 (COVID-19)Health PersonnelRetinal pathology / researchSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Context (language use)medicine.disease_causeRetinaAntimalarials03 medical and health sciences0302 clinical medicineRetinal DiseasesChloroquineInternal medicinePandemicmedicineHumansRETINARetina – medical therapiesCoronavirusPharmacologyOphthalmologistsSARS-CoV-2business.industryCOVID-19ChloroquineHydroxychloroquineGeneral MedicineSystemic drug retinal ToxicityTechniques of retinal examinationCOVID-19 Drug TreatmentCoronavirusClinical trialOphthalmology030104 developmental biologyCaregiversMedicina Preventiva y Salud Pública030221 ophthalmology & optometryHuman medicinebusinessHydroxychloroquinemedicine.drugEuropean journal of ophthalmology
researchProduct

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: …

2020

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treat…

0301 basic medicinemedicine.medical_specialtyESMO guidelinesDrug availability03 medical and health sciences0302 clinical medicineAdvanced diseaseAsian countryconsensuMedicineHCCReimbursementESMO guidelinePan-Asianbusiness.industryCancer conferenceRelapsed Hepatocellular CarcinomaHematologyhepatocellular carcinomaClinical Practice030104 developmental biologyOncologyconsensus030220 oncology & carcinogenesisFamily medicinebusiness
researchProduct